Efrat Zlotkin-Rivkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Efrat Zlotkin-Rivkin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Aroeti
Department of Biological Chemistry; The Alexander Silberman Institute of Life Sciences; The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram
2 shared publications - Ipsita Nandi
Department of Biological Chemistry; The Alexander Silberman Institute of Life Sciences; The Hebrew University of Jerusalem, The Edmond J. Safra Campus – Givat Ram
2 shared publications - Alexander Rouvinski
Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel
1 shared publication - Deborah E. Shalev
Wolfson Centre for Applied Structural Biology The Hebrew University of Jerusalem Jerusalem 9190401 Israel
1 shared publication - Dina Schneidman-Duhovny
The Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel
1 shared publication - Hanan Schoffman
Proteomics and Mass Spectrometry Unit, The Alexander Silberman Institute of Life Sciences; The Hebrew University of Jerusalem
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2595775
The ubiquitin system targets translocated EspH to proteasomal degradation
EspH is an effector protein secreted by the type III secretion system of various pathogenic Escherichia coli strains, including enteropathogenic E. coli (EPEC). The ability of EspH to inhibit host RhoGTPases, disrupt the actin cytoskeleton, and induce host cell cytotoxicity has been well-documented. Mass spectrometry analysis of EspH translocated into EPEC-infected cells revealed that a lysine at position 106 (K106) is modified with ubiquitin. Immunoblotting using the FK2 anti-ubiquitin antibodies has confirmed these results, suggesting that EspH undergoes polyubiquitylation. Prediction algorithms have identified a single ubiquitylation site at K106 and a phosphodegron in EspH. Moreover, we show that wild-type (EspHwt), but not the EspHK106R mutant, is subjected to degradation following translocation in an MG132-sensitive manner, indicating that the proteasome degrades the polyubiquitylated effector following translocation. Finally, we show that translocated EspHK106R induces higher cytotoxicity than translocated EspHwt. EspHwt translocated into MG132-pretreated cells also displayed higher cytotoxicity levels than EspHwt in untreated cells. These data reinforce the idea that EspH is polyubiquitylated and that the host proteasome degrades the translocated effector, possibly limiting its ability to toxicate the host cells. Additional implications of these effects on bacterial-host interactions are discussed.
- 4 December 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2595775
Open AccessThe ubiquitin system targets translocated EspH to proteasomal degradation
EspH is an effector protein secreted by the type III secretion system of various pathogenic Escherichia coli strains, including enteropathogenic E. coli (EPEC). The ability of EspH to inhibit host RhoGTPases, disrupt the actin cytoskeleton, and induce host cell cytotoxicity has been well-documented. Mass spectrometry analysis of EspH translocated into EPEC-infected cells revealed that a lysine at position 106 (K106) is modified with ubiquitin. Immunoblotting using the FK2 anti-ubiquitin antibodies has confirmed these results, suggesting that EspH undergoes polyubiquitylation. Prediction algorithms have identified a single ubiquitylation site at K106 and a phosphodegron in EspH. Moreover, we show that wild-type (EspHwt), but not the EspHK106R mutant, is subjected to degradation following translocation in an MG132-sensitive manner, indicating that the proteasome degrades the polyubiquitylated effector following translocation. Finally, we show that translocated EspHK106R induces higher cytotoxicity than translocated EspHwt. EspHwt translocated into MG132-pretreated cells also displayed higher cytotoxicity levels than EspHwt in untreated cells. These data reinforce the idea that EspH is polyubiquitylated and that the host proteasome degrades the translocated effector, possibly limiting its ability to toxicate the host cells. Additional implications of these effects on bacterial-host interactions are discussed.
- Open Access
- 23 September 2024
- Published by Taylor & Francis in Gut Microbes
- Vol. 16 (1) , 2400575
EspH utilizes phosphoinositide and Rab binding domains to interact with plasma membrane infection sites and Rab GTPases*
Enteropathogenic E. coli (EPEC) is a Gram-negative bacterial pathogen that causes persistent diarrhea. Upon attachment to the apical plasma membrane of the intestinal epithelium, the pathogen translocates virulence proteins called effectors into the infected cells. These effectors hijack numerous host processes for the pathogen's benefit. Therefore, studying the mechanisms underlying their action is crucial for a better understanding of the disease. We show that translocated EspH interacts with multiple host Rab GTPases. AlphaFold predictions and site-directed mutagenesis identified glutamic acid and lysine at positions 37 and 41 as Rab interacting residues in EspH. Mutating these sites abolished the ability of EspH to inhibit Akt and mTORC1 signaling, lysosomal exocytosis, and bacterial invasion. Knocking out the endogenous Rab8a gene expression highlighted the involvement of Rab8a in Akt/mTORC1 signaling and lysosomal exocytosis. A phosphoinositide binding domain with a critical tyrosine was identified in EspH. Mutating the tyrosine abolished the localization of EspH at infection sites and its capacity to interact with the Rabs. Our data suggest novel EspH-dependent mechanisms that elicit immune signaling and membrane trafficking during EPEC infection.
- 23 September 2024
- Published by Taylor & Francis in Gut Microbes
- Vol. 16 (1) , 2400575
Open AccessEspH utilizes phosphoinositide and Rab binding domains to interact with plasma membrane infection sites and Rab GTPases*
Enteropathogenic E. coli (EPEC) is a Gram-negative bacterial pathogen that causes persistent diarrhea. Upon attachment to the apical plasma membrane of the intestinal epithelium, the pathogen translocates virulence proteins called effectors into the infected cells. These effectors hijack numerous host processes for the pathogen's benefit. Therefore, studying the mechanisms underlying their action is crucial for a better understanding of the disease. We show that translocated EspH interacts with multiple host Rab GTPases. AlphaFold predictions and site-directed mutagenesis identified glutamic acid and lysine at positions 37 and 41 as Rab interacting residues in EspH. Mutating these sites abolished the ability of EspH to inhibit Akt and mTORC1 signaling, lysosomal exocytosis, and bacterial invasion. Knocking out the endogenous Rab8a gene expression highlighted the involvement of Rab8a in Akt/mTORC1 signaling and lysosomal exocytosis. A phosphoinositide binding domain with a critical tyrosine was identified in EspH. Mutating the tyrosine abolished the localization of EspH at infection sites and its capacity to interact with the Rabs. Our data suggest novel EspH-dependent mechanisms that elicit immune signaling and membrane trafficking during EPEC infection.